key: cord-0927747-dcbggxlq
authors: Fukushi, Shuetsu
title: Competitive ELISA for the Detection of Serum Antibodies Specific for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
date: 2020-05-11
journal: Coronaviruses
DOI: 10.1007/978-1-0716-0900-2_4
sha: 52610d43dbb2568348e85534b51fc9d5157f3d38
doc_id: 927747
cord_uid: dcbggxlq

Middle East respiratory syndrome coronavirus (MERS-CoV) is the etiological agent of MERS, a severe respiratory disease first reported in the Middle East in 2012. Serological assays are used to diagnose MERS-CoV infection and to screen for serum antibodies in seroepidemiological studies. The conventional enzyme-linked immunosorbent assay (ELISA) is the preferred tool for detecting serum antibodies specific for pathogens; however, the utility of conventional ELISA with respect to detection of MERS-CoV antibodies is limited due to the number of false-positives caused by cross-reactivity of serum antibodies with antigens that are conserved among coronaviruses. The competitive ELISA (cELISA) uses a pathogen-specific monoclonal antibody (MAb) that competes with serum antibodies for binding to an antigen; therefore, it is used widely for serological surveillance of many pathogens. In this chapter, I describe detection of serum antibodies using cELISA based on MAbs specific for MERS-CoV.

Middle East respiratory syndrome (MERS) is a severe respiratory illness first reported in the Middle East in 2012; it is caused by a newly recognized coronavirus called MERS-CoV [1] . Humans are infected with MERS-CoV through direct or indirect contact with dromedary camels, indicating that dromedary camels are the amplifying host and a major source of zoonotic infection [2, 3] . Since the discovery of MERS-CoV, serological antibody assays have been developed to assess antibody responses of infected patients and to investigate the seroprevalence of MERS [4] [5] [6] . Virus neutralization assays are the gold standard for detecting antibodies specific for MERS-CoV because they are both specific and sensitive [7] . However, conventional virus neutralization assays require handling of infectious MERS-CoV under biosafety level (BSL)-3 conditions. Furthermore, it takes several days to obtain results because detectable levels of virus replication in virus infected cells are required.

General laboratories lacking heightened biocontainment facilities can use replication-incompetent pseudotyped viruses bearing viral glycoproteins to detect neutralizing antibodies and to investigate the mechanism underlying virus entry into host cells. Indeed, studies show the utility of a high-throughput pseudotyped virus system for detecting neutralizing antibody responses against MERS-CoV and to search for drugs that inhibit entry of MERS-CoV into cells [8] [9] [10] . The major advantage of the MERS-CoV pseudotype is that it can be handled without the need for BSL-3 conditions. However, the pseudotype system is not always a versatile approach since it requires equipment for cell culture, along with machines able to measure fluorescence or chemiluminescence to detect pseudotype infection; such a system is not readily adaptable to rural areas or developing countries in which the availability of expensive equipment is limited. Furthermore, the method used to generate the pseudotype virus is tricky; for example, carboxylterminal truncation of the MERS-CoV spike (S) protein might be needed to generate a high titer of the vesicular stomatitis virusbased MERS-CoV pseudotype [10] .

Enzyme-linked immunosorbent assay (ELISA) is used widely in general clinical laboratories to measure serum antibody responses. Binding of serum antibodies to an antigen attached to a microplate generates a colorimetric reaction that is detected by a microplate reader; most importantly, ELISAs do not require specialized techniques. However, the usefulness of these assays for detecting anti-MERS-CoV antibodies is limited by the fact that antibodies that bind to conserved proteins expressed by coronaviruses are often cross-reactive; therefore, these assays often yield false-positive reactions [7, 11, 12] .

The competitive ELISA (cELISA) was developed to detect serum antibody responses against many viruses [13] [14] [15] [16] . It is based on a labeled monoclonal antibody (MAb) that is specific for a target antigen; this antibody competes with serum antibodies for binding to the antigen, thereby enabling detection and measurement of pathogen-specific antibodies (Fig. 1) . Furthermore, since cELISA does not require a species-specific secondary antibody, it has an advantage over conventional ELISA in that it can detect serum antibodies in any animal species, making it a useful tool for seroepidemiological surveillance of MERS. Neutralizing responses to MERS-CoV in test serum can be measured using cELISA when the labeled MAb recognizes neutralizing epitopes in the MERS-CoV S protein [17] . Comparison with the results generated by a neutralization assay using live MERS-CoV shows that the results of cELISA correlate well with neutralization antibody titers [17] . The following protocol describes detection of serum antibodies using a cELISA based on a MAb specific for MERS-CoV. 2. Positive control antibody (serum from a rabbit immunized with the MERS-CoV S protein expressed in a recombinant baculovirus expression system, inactivated at 56 C for 30 min) [10] .

3. Test serum (inactivated at 56 C for 30 min).

4. MERS-CoV antigen cell slurry (see Note 2) or purified recombinant RBD antigen (rRBD, see Note 3). 9. Take 55 μl of the 32-fold diluted serum sample (line D) and mix with 55 μl blocking buffer to make a 64-fold dilution (line E). 10 . Take 55 μl of the 64-fold diluted serum sample (line E) and mix with 55 μl blocking buffer to make a 128-fold dilution (line F).

11. Take 55 μl of the 128-fold diluted serum sample (line F) and mix with 55 μl blocking buffer to make a 256-fold dilution (line G). Discard 55 μl of the mixture.

12. Place the nonserum control in line H. 13 . In the dispenser tray, prepare a 2340-fold dilution of biotinylated MAb 45C2 (e.g., mix 6 μl of biotinylated 45C2 with 14 ml of blocking buffer).

14. Using the 12-channel pipette, take 55 μl of diluted biotinylated 45C2 (prepared in 13 above) and mix with 55 μl of serially diluted serum sample (final serum dilutions range from 8 to 512) and nonserum control in a U-bottom microplate (prepared in 12 above). Pipette tips should be replaced after mixing each sample (Fig. 4) . 15 . After blocking, wash the ELISA plate twice with 300 μl PBS-T. 16. Transfer 100 μl of the serum-antibody mixture from the U-bottom microplate (prepared in 14 above) to the ELISA plate (prepared in 15 above) (Fig. 5) (Fig. 6 ).

2. The cutoff values of % inhibition for each serum dilution can be determined using at least ten negative serum samples. 3. The antibody titer is determined by performing cELISA with twofold serial dilutions (from 8-to 512-fold) of serum samples and is expressed as the reciprocal of the highest dilution at which % inhibition is above the cut-off value for each serum dilution.

4. Comparison with the results of a neutralization assay using live MERS-CoV allows for confirmation that the results of the cELISA correlate well with neutralizing antibody titers [17] .

1. To generate MAb 45C2 (specific for the MERS-CoV antigen), BALB/c mice are immunized with purified, UV-inactivated MERS-CoV particles [17] . Hybridoma cells are produced by fusing mouse myeloma cells with splenic cells isolated from the [17] . Ask the author to share the MAb; this can be done formally using a material transfer agreement (MTA). A MAb specific for the MERS-CoV RBD is also available commercially (Absolute antibody, Wilton, UK); however, detailed characterization (specificity, epitopes, etc.) of this MAb might be required. 3. Recombinant RBD (rRBD) can be used as an alternative antigen for the cELISA. To prepare rRBD from MERS-CoV, the mammalian expression plasmid pCAGGS-RBD, which encodes histidine-tagged MERS-CoV RBD (amino acid 358-588), is transfected to 293T cells. At 2 days post-transfection, the rRBD is purified from the supernatant using a His-Bind Purification Kit. The amount of purified rRBD protein is determined using a BCA protein assay kit. Ask the author to share the rRBD; this can be done formally using an MTA. A commercial MERS-CoV S antigen (e.g., MERS-CoV S1 subunit protein; CD Creative Diagnostics, Shirley, NY, or Sino Biological, Beijing, China) might be available for use in the cELISA.

4. To screen serum antibodies from a large number of samples, it is better to test first at a single serum dilution (fourfold dilution) and then serially dilute only samples that are antibodypositive to measure antibody titers.

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans

Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates

Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan

Geographic distribution of MERS coronavirus among dromedary camels

Acute middle east respiratory syndrome coronavirus infection in livestock dromedaries

Serological assays for emerging coronaviruses: challenges and pitfalls

Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt

Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity

Inability of rat DPP4 to allow MERS-CoV infection revealed by using a VSV pseudotype bearing truncated MERS-CoV spike protein

Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections

A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus

Monoclonal antibody-based ELISA for detection of antibodies against H5 avian influenza viruses

Seroprevalence of Rift Valley fever virus in sheep and goats in Zambezia

A competitive ELISA for detection of group specific antibody to bluetongue virus using anti-core antibody

Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the west African Ebola epidemic 2014-2016: a cross-sectional study

Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA

cELISA for Detection of MERS-CoV Serum Antibodies

This work was supported, in part, by a grant from the Japan Agency for Medical Research and Development (AMED) (# JP19fk0108058).cELISA for Detection of MERS-CoV Serum Antibodies